Health ❯ Healthcare ❯ Clinical Trials

Drug Efficacy

Patient Outcomes Weight Loss Results Side Effects Combination Therapy Semaglutide Weight Loss Drugs Weight Loss Medications Weight Loss Trials Comparative Studies Lenacapavir GLP-1 Receptor Agonists Wegovy Trials Wegovy Weight Loss Studies Cognitive Decline Weight Loss Outcomes Novo Nordisk Orforglipron Lecanemab Trials Patient Safety Leqembi Baxdrostat Lecanemab Obesity Treatments Semaglutide Trials Alzheimer's Treatments Zepbound EMPACT-MI Trial Nuzolvence and Blujepa Ruxolitinib Trials Lecanemab and Donanemab Weight-loss Injections Weight Maintenance Statin Therapy Capivasertib Trials Solriamfetol Pembrolizumab Orforglipron vs Semaglutide Placebo Effect Vutrisiran Cognitive Impairment Retatrutide Trials Weight Regain Studies CagriSema Skin Clearance Elamipretide Cardiovascular Protection Semaglutide and Tirzepatide STEP UP Trial Head-to-Head Trials Addyi Ubrogepant Influenza Prevention International Studies Weight Management Expert Opinions Phase Three Trials Talazoparib and Enzalutamide Mounjaro Trials Pre-exposure Prophylaxis (PrEP) Wegovy Study Results Hidradenitis Suppurativa Nirsevimab Trials Myotonic Dystrophy Type 1 Orforglipron Study Results COVID-19 Studies Tirzepatide Study Palivizumab Donanemab Kisunla Long-term Effects Amycretin Amycretin Studies Mounjaro Results Enlicitide Trial GLP-1 Clinical Research Enfortumab Vedotin and Pembrolizumab Evidence-Based Medicine Gonorrhea Treatment Ivermectin Zanubrutinib and Venetoclax Ivonescimab Vasomotor Symptoms Biosimilar Efficacy COPD Treatments Lynkuet FDA Approval Process Monoclonal Antibodies Teplizumab Trials Obexelimab Alzheimer's Treatment Sub-Saharan Africa Weight Loss Injections Amycretin Trials Alyftrek Results Early Stage Trials Real-World Evidence Eli Lilly Phase 3 Trials Asthma Exacerbations

New Trials Show Daily Pills Can Help Maintain Weight Loss After GLP-1 Injections

The findings point to a shift toward long-term care that favors simple daily tablets for maintaining results.

EMA Validates Astellas Bid to Add Padcev–Keytruda Combo for Perioperative Muscle-Invasive Bladder Cancer

India’s Generic Semaglutide Wave Eats Into Mounjaro’s Lead as Novo Holds Share

FDA Clears Eli Lilly’s Foundayo Oral GLP-1 for Weight Loss, With U.S. Launch Set for April 6

FDA Clears Lilly’s Foundayo Pill, Escalating GLP-1 Weight-Loss Rivalry

Sarepta Reports Early siRNA Data Showing Muscle Delivery as Shares Surge

FDA Clears J&J’s Icotyde, First Oral IL-23 Psoriasis Therapy for Ages 12 and Up

For Third Time, FDA Rejects Aldeyra’s Dry-Eye Drug Reproxalap Over Efficacy

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

NICE Recommends First Vitiligo Repigmentation Cream for NHS Use in England

Lilly Launches FDA-Cleared Monthly Zepbound KwikPen on LillyDirect at $299 Starter Price

GLP‑1 Use Under Scrutiny After Study on Tolerability and Delhi OTC Sales

Randomized Trial Finds Solriamfetol Improves Alertness in Early-Morning Shift Workers

NICE Endorses Dupilumab as First Targeted Biologic for Uncontrolled Eosinophilic COPD

Zenas' Obexelimab Meets Phase 3 Goals in IgG4-Related Disease With 56% Flare Risk Cut

Neurocrine’s Valbenazine Misses Phase 3 Goals in Dyskinetic Cerebral Palsy

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

FDA Expands Addyi Use to Postmenopausal Women, Including Those Over 65

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

FDA Approves Poherdy as First Interchangeable Biosimilar to Perjeta for HER2-Positive Breast Cancer